Drug profile · INN
niraparib
ZEJULA
niraparib (ZEJULA) is a poly [adp-ribose] polymerase-1 inhibitor. Associated with GlaxoSmithKline.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01
Patents linked 0
Pipeline programs 25
News articles 0
Drug details — niraparib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 25
- Data quality
- 0.83
Quick answer
niraparib (ZEJULA) is a poly [adp-ribose] polymerase-1 inhibitor. Associated with GlaxoSmithKline.
Key facts
INN niraparib
Brand ZEJULA
Mechanism Poly [ADP-ribose] polymerase-1 inhibitor
Target Poly [ADP-ribose] polymerase 2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01
Originator GlaxoSmithKline
Mechanism of action
Poly [ADP-ribose] polymerase-1 inhibitor
Primary target: Poly [ADP-ribose] polymerase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is niraparib?
niraparib (ZEJULA) is a poly [adp-ribose] polymerase-1 inhibitor. Associated with GlaxoSmithKline.
What is the brand name for niraparib?
ZEJULA is a marketed brand name for niraparib. Check FDA Drugs@FDA for the current US label holder and prescribing information.